The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...

Attention-deficit/hyperactivity disorder (ADHD) is a common but complex neurodevelopmental condition characterized by symptoms of inattention, hyperactivity, and ...

This graph visualizes how the trials included in the meta-analysis compared the effectiveness of different treatment strategies. The width of the lines connecting each treatment reflects the number of ...

Attention-deficit/hyperactivity disorder is one of the most researched neurodevelopmental conditions, yet 5 ADHD myths people ...

Long-term methylphenidate use in childhood links to higher adult BMI and slightly shorter height, underscoring the need for ...

ADHD New Zealand spokesperson Darrin Bull joins Mike Hosking to discuss the significant prescription law change that will make ADHD treatment easier to acc ...

Are you or your loved one struggling with the overwhelming effects of trauma, PTSD, or substance abuse? Perhaps your child is facing challenges with ADHD, autism spectrum disorders, or behavioral ...

BLACKSBURG, Va. – A study at Virginia Tech is working to discover if learning to DJ could help improve symptoms of ADHD.

Boys who stopped ADHD treatment at higher risk for negative consequences. Oct. 16, 2012 — -- Young boys who discontinue treatment for attention deficit hyperactivity disorder (ADHD) are featured ...